DWP217 / Daewoong Pharma - LARVOL DELTA

DWP217, a novel Arginase inhibitor enhancing tumor immunity through tumor microenvironment reprogramming (AACR 2025) - "With its strong preclinical efficacy and favorable immune modulation profile, DWP217 is a promising therapeutic candidate for overcoming immuno-oncology resistance. Its further development holds the potential to significantly improve therapeutic outcomes in refractory solid tumors."

Biomarker • Tumor microenvironment • Oncology • Solid Tumor

Daewoong Pharmaceutical to unveil 3 anticancer pipelines at AACR 2025 (Korea Biomedical Review) - "Daewoong Pharmaceutical, a Korean drugmaker, said on Friday that it will unveil three anticancer pipelines at the 2025 American Association for Cancer Research (AACR) annual meeting, taking place from April 25 to 30 in Chicago, the U.S. The three investigational drugs are targeted therapy DWP216, immunotherapy DWP217, and synthetic lethality drug DWP223....Daewoong will showcase preclinical results of these three candidate drugs in four posters....DWP216 reduced cancer cell resistance and enhanced the effectiveness of existing anticancer drugs in non-small cell lung cancer and pancreatic cancer with EGFR and KRAS mutations. DWP217, the immunotherapy, proved more effective than current arginase inhibitors in animal studies, improving the immunosuppressive tumor environment and enabling immune cells to attack cancer more aggressively. DWP223, the synthetic lethality drug, showed potent anti-cancer effects at low doses in animal studies."

Preclinical • Non Small Cell Lung Cancer